All Novasep Synthesis sites pass FDA inspections in last three years

Novasep’s pharmaceutical production excellence in Europe and the Bahamas recognized by two successful FDA inspections in 2011

29-Jul-2011 - Novasep announced today that it has completed two successful US Food and Drug Administration (FDA) inspections for Novasep Synthesis in 2011. All five Novasep Synthesis sites passed FDA inspections in the last three years, the most recent ones at its Freeport (the Bahamas) facility in March 2011 ...

Novasep and instrAction expand alliance to include taxane purification

Companies will develop solutions to change manufacturing paradigm for new and generic anti-cancer compounds

15-Feb-2011 - Novasep, a leading supplier of manufacturing solutions to the life science industries, and instrAction, a manufacturer of innovative chromatographic stationary phases for API purification processes, announced they have expanded their worldwide strategic alliance to include the purification of ...

Novasep Process and Nutritis scale-up the production process for Nutritis’ fructose purification from substandard fruit

11-Nov-2010 - Nutritis and Novasep Process, a division of Novasep, announced that, thanks to Novasep Process, Nutritis will scale up its production process for fructose from apple juice. Nutritis brought in Novasep to use the latter’s purification expertise to scale up its innovative process. Nutritis and ...

Novasep Appoints a New Chairman for its Supervisory Board

Bernard Dubois, Former Aventis Senior VP of Global Industrial Operations Brings a Wealth of Experience to Novasep's Top Management Team

06-Sep-2010 - Novasep announced the appointment of Bernard Dubois as Chairman of its supervisory board. Bernard Dubois replaces Pietro Stefanutti, who decided to allocate most of his time to personal activities. As a graduate of the renowned Ecole Polytechnique (France) with an MBA from Cornell University ...

Cerenis and Novasep awarded €10.7 million funding from the French Government for the development CER-001, an HDL mimetic

27-Jul-2010 - Cerenis Therapeutics SA and Groupe Novasep announced that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic. CER-001 represents a promising new approach in the fight against atherosclerotic cardiovascular disease and has shown ...

Novasep and instrAction enter a worldwide strategic alliance for non-chiral chromatography

21-Jul-2010 - Novasep and instrAction announced that they have entered a strategic alliance. The alliance will offer customers in the life science industry a combination of instrAction’s proprietary API-selective stationary phases (Instruction® Receptor Phase) and Novasep purification capabilities and high ...

Novasep appoints two key executives

Stephen Stefano heads up Novasep North American business and Patrick Glaser leads Novasep Synthesis division

05-May-2010 - Novasep announced the appointments of two highly experienced managers in its drive to grow the group’s US presence and develop its Novasep Synthesis division. Stephen F. Stefano becomes President and CEO of Novasep North American business, and Patrick A. Glaser President and CEO of the Novasep ...